Clinical Report: FDA clears targeted cholangiocarcinoma therapy
Overview
The FDA has approved lirafugratinib for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements. The approval is based on the REFOCUS trial, which demonstrated a 46% objective response rate and a median response duration of 11.8 months.
Background
Cholangiocarcinoma is a rare and aggressive malignancy with limited treatment options, particularly for patients with unresectable or metastatic disease. Targeted therapies, such as those inhibiting fibroblast growth factor receptors (FGFR), are being explored for this patient population.
Data Highlights
Measure
Value
Objective Response Rate
46%
Median Duration of Response
11.8 months
Recommended Dose
70 mg once daily
Key Findings
Lirafugratinib is approved for adults with unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements.
The REFOCUS trial enrolled 116 patients and reported an objective response rate of 46%.
The median duration of response for lirafugratinib was 11.8 months.
Key safety warnings include ocular toxicity, hyperphosphatemia, and embryo-fetal toxicity.
Lirafugratinib received breakthrough therapy and orphan drug designations from the FDA.
Clinical Implications
Healthcare providers should monitor for potential side effects, particularly ocular toxicity and hyperphosphatemia, during treatment with lirafugratinib.
Conclusion
The approval of lirafugratinib marks a significant advancement in the treatment of cholangiocarcinoma, providing a targeted therapy option for a challenging patient population.
Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
Investigators compared intra-articular microbial profiles and predicted metabolic pathways in patients with hip osteoarthritis and nonarthritic controls.
